Cell phenotypes as activity biomarkers in patients with Systemic Lupus Erythematosus

Authors

  • Cristina de Mello Gomide Loures Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Tânia Mara Pinto Dabés Guimarães Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Karine Silveste Ferreira Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Marcos Vinicius Ferreira Silva Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Luan Carlos Vieira Alves Department of Clinical and Toxicological Analysis https://orcid.org/0000-0002-9024-8872
  • Fernanda Freire Campos Nunes Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Renato Vargas Consoli Department of Rheumatology, Santa Casa, Belo Horizonte, Minas Gerais, Brazil
  • Cláudia Lopes Santoro Neiva Department of Rheumatology, Santa Casa, Belo Horizonte, Minas Gerais, Brazil
  • Paulo Madureira de Pádua Department of Rheumatology, Santa Casa, Belo Horizonte, Minas Gerais, Brazil
  • Luara Isabela dos Santos Oswaldo Cruz Foundation, Belo Horizonte, Minas Gerais, Brazil
  • Josimar Dornelas Moreira Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Vicente de Paulo Coelho Peixoto de Toledo Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • Maria das Graças Carvalho Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil https://orcid.org/0000-0002-1669-3302

DOI:

https://doi.org/10.1590/s2175-97902023e20052

Keywords:

Systemic Lupus Erythematosus; Lupus nephritis; T cells; B cells; NK cells

Abstract

The pathogenesis of systemic lupus erythematosus (SLE) is complex. Few studies in Brazilian population have addressed cell phenotypes associated with immunological responses and their associations with SLE activity. The aim of this study is to investigate cell phenotypes associated to SLE diagnosis, treatment and activity. Twenty-eight SLE female patients (17 inactive, 11 active) and 10 healthy women were included in this study. Markers of natural killer (Nk), T and B cells in peripheral blood were evaluated by flow cytometry. Nkt cells were decreased only in SLE active patients. Activated CD4+, regulatory T FoxP3+ and B cells were decreased in both active and inactive SLE patients, compared to control group. The data corroborate the disruption of immune regulatory response in SLE patients and suggest phenotipic changes as possible biomarkers of SLE activity.

Downloads

Download data is not yet available.

References

Afzali B, Mitchell P, Lechler RI, John S, Lombardi G. Translational mini-review series on Th17 cells: induction of interleukin 17 production by regulatory T cells. Clin Exp Immunol. 2010;159(2):120-130.

Ahearn JM, Liu CC, Kao AH, Manzi S. Biomarkers for Systemic Lupus Erythematosus. Transl Res. 2012;159(4):326-342.

Alvarado-Sánchez B, Hernández-Castro B, Portales-Pérez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, et al. Regulatory T cells in patients with Systemic Lupus Erythematosus. J Autoimmun. 2006;27(2):110-118.

Ben ERRD, Prado CH, Baptista TSA, Bauer ME, Staub HL. Patients with Systemic Lupus Erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4+CD25+Foxp3+ Treg and CD3- CD19+ B cells. Rev Bras Reumatol. 2014;54(3):241-246.

Bijl M, Horst G, Limburg PC, Kallenberg CG. Fas expression on peripheral blood lymphocytes in Systemic Lupus Erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus. 2001;10(12):866-872.

Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with Systemic Lupus Erythematosus. Arthritis Rheum. 2005;52(1):201-211.

Boerman GH, van Ostaijen-ten Dam MM, Kraal KC, Santos SJ, Ball LM, Lankester AC, et al. Role of NKG2D, DNAM- 1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. Cancer Immunol Immunother. 2015;64(5):573-83.

Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of Systemic Lupus Erythematosus. Autoimmun Rev. 2010;9(5):277-287.

Chang NH, McKenzie T, Bonventi G, Landolt-Marticorena C, Fortin PR, Gladman DD, et al. Expanded population of activated antigen-engaged cells within the naive B cell compartment of patients with Systemic Lupus Erythematosus. J Immunol. 2008;180(2):1276-1284.

Cheen J, Wu M, Wang J, Li X. Immunoregulation of NKT Cells in Systemic Lupus Erythematosus. J Immunol Res. 2015;2015:206731.

Cho YN, Kee SJ, Lee SJ, Seo SR, Kim TJ, Lee SS, et al. Numerical and functional deficiencies of natural killer T cells in Systemic Lupus Erythematosus: their deficiency related to disease activity. Rheumatology (Oxford). 2011;50(6):1054-1063.

Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with Systemic Lupus Erythematosus. J Autoimmun . 2003;21(3):273-276.

Crispin JC, Keenan BT, Finnell MD, Bermas BL, Schur P, Massarotti E, et al. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with Systemic Lupus Erythematosus and is correlated with disease activity. Arthritis Rheum . 2010;62(5):1431-1437.

Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun . 2013;41:25-33.

Daca A, Czuszyńska Z, Smoleńska Z, Zdrojewski Z, Witkowski JM, Bryl E. Two Systemic Lupus Erythematosus (SLE) global disease activity indexes-the SLE Disease Activity Index and the Systemic Lupus Activity Measure-demonstrate different correlations with activation of peripheral blood CD4+ T cells. Hum Immunol. 2011;72(12):1160-1167.

Dolff S, Wilde B, Patschan S, Dürig J, Specker C, Philipp T, et al. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with Systemic Lupus Erythematosus. Scand J Immunol . 2007;66(5):584-590.

Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CG, Abdulahad WH. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with Systemic Lupus Erythematosus. Clin Immunol. 2011;141(2):197-204.

Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.

Goropevšek A, Gorenjak M, Gradišnik S, Dai K, Holc I, Hojs R, et al. Increased Levels of STAT1 Protein in Blood CD4 T Cells from Systemic Lupus Erythematosus Patients Are Associated with Perturbed Homeostasis of Activated CD45RA- FOXP3hi Regulatory Subset and Follow-Up Disease Severity. J Interferon Cytokine Res. 2017;37(6):254-268.

Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer cell activity in families of patients with Systemic Lupus Erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol . 2005;141(1):165-173.

Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer T cells in families of patients with Systemic Lupus Erythematosus: their possible role in regulation of IGG production. Arthritis Rheum . 2007;56(l):303-310.

Guo H, Xu B, Gao L, Sun X, Qu X, Li X, et al. High frequency of activated natural killer and natural killer T-cells in patients with new onset of type 2 diabetes mellitus. Exp Biol Med (Maywood). 2012;237(5):556-562.

Henriques A, Teixeira L, Inês L, Carvalheiro T, Gonçalves A, Martinho A, et al. NK cells dysfunction in Systemic Lupus Erythematosus: relation to disease activity. Clin Rheumatol. 2013;32(6):805-813.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of Systemic Lupus Erythematosus. Arthritis Rheum . 1997;40(9):1725.

Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, et al. Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort. Lupus. 2019;28:295-303.

Iwata Y, Furuichi K, Kaneko S, Wada T. The role of cytokine in the lupus nephritis. J Biomed Biotechnol. 2011;594809.

Kleczynska W, Jakiela B, Plutecka H, Milewski M, Sanak M, Musial J. Imbalance between Th17 and regulatory T-cells in Systemic Lupus Erythematosus. Folia Histochem Cytobiol. 2011;49(4):646-653.

Le Coz C, .Joublin A, Pasquali JL, Korganow AS, Dumortier H, Monneaux F. Circulating TFH Subset Distribution Is Strongly Affected in Lupus Patients with an Active Disease. PLoS One. 2013;8(9):e75319.

Li WX, Pan HF, Hu JL, Wang CZ, Zhang N, Li J, et al Assay of T-and NK-cell subsets and the expression. of NKG2A and NKG2D in patients with new-onset Systemic Lupus Erythematosus. Clin Rheumatol . 2010;29:315-323.

Mathian A, Hie A, Cohen-Aubart F, Amoura Z. Targeting interferons in Systemic Lupus Erythematosus, Current and future prospects. Drugs. 2015;75(8):835-846.

Nakashima CAK, Galhardo AP, Silva JFM, Fiorenzano GR, Santos ABS, Leite MFS, et al. Incidência e aspectos clínico- laboratoriais do Lúpus eritematoso sistêmico em cidade do Sul do Brasil. Rev Bras Reumatol . 2011;51(3): 235-239.

Rahman A, Isenberg DA. Systemic Lupus Erythematosus. N Engl J Med. 2008;358(9):929-939.

Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Kärre K, et al. Increased proportion of CD56bright natural killer cells in active and inactive Systemic Lupus Erythematosus. Immunology. 2009;126(1):140-146.

Schleinitz N, Vély F, Harlé JR, Vivier E. Natural killer cells in human autoimmune diseases. Immunology. 2010;131(4):451-458.

Spada R, Rojas JM, Pérez-Yagüe S, Mulens V, Cannata-Ortiz P, Bragado R, et al. NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leukoc Biol. 2015;97(3):583-598.

Soares MF, Telles JEQ, Moura LA. Classifications of lupus nephritis: metanalysis and the ISN/RPS proposal. J Bras Nefrol. 2005;27(3):157-162.

Takeuchi T, Tsuzaka K, Kameda H, Amano K. Molecular abnormalities of T-cells in Systemic Lupus Erythematosus. APLAR J Rheumatol . 2006;9(4):365-371.

Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239-244.

Wouters CH, Diegenant C, Ceuppens JL, Degreef H, Stevens EA. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and Systemic Lupus Erythematosus suggest a pathogenetic relationship. Br J Dermatol. 2004;150(4):693-670.

Yu S, Fujio K, Ishigaki K, Shoda H, Okamura T, Noor T, et al. Increased concentration of serum soluble LAG3 in Systemic Lupus Erythematosus. Arthritis Res Ther. 2012;14(1):16.

Zhu L, Yin Z, Ju C, Zhang J, Wang Y, Lv X, et al. Altered frequencies of memory B cells in new-onset Systemic Lupus Erythematosus patients. Clin Rheumatol . 2018;37(1):205-212.

Downloads

Published

2023-04-28

Issue

Vol. 59 (2023)

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.

The on line journal has open and free access.

How to Cite

Cell phenotypes as activity biomarkers in patients with Systemic Lupus Erythematosus. (2023). Brazilian Journal of Pharmaceutical Sciences, 59, e20052. https://doi.org/10.1590/s2175-97902023e20052